Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program (Protocol CHRC-002)

Trial ID:
IRB-13-6079
Thomas Heywood
This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III & IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II & FC I patients.

Inclusion Criteria:

  • 1. Male and female adults (>/= 18 years of age)
  • 2. Documented diagnosis of pulmonary arterial hypertension (PAH) (all of the following):
    • i. Right Heart Catheterization (RHC) demonstrating mean Pulmonary Arterial Pressure (mPAP) > 25mm Hg and Pulmonary Capillary Wedge Pressure (PCWP) ii. Forced Expiratory Volume in the first second (FEV1) > 50% predicted normal iii. Ventilation/Perfusion (V/Q) and/or Computerized Tomography (CT) scan excluding the thromboembolic etiology

  • 3. Diagnosis of PAH < 3 years
  • 4. Need for PAH specific treatment
  • 5. Desire to participate and signs an Informed Consent.

Exclusion Criteria:

    Any of the criteria below:

    • Poor mental function, drug or substance (e.g., alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study;
    • Prior participation in this program; c. Patients with pulmonary hypertension classified as group 2 - 5 Dana Point, 2008 updated clinical classification.